KR-20260062910-A - COMPOSITION FOR IMPROVING MEMORY OR COGNITION ABILITY, OR PREVENTING OR TREATING BRAIN NEUROLOGICAL DISEASES, COMPRISING PORCINE BRAIN ENZYME HYDROLYSATE

Abstract

The present invention relates to a composition for improving memory, improving cognitive ability, and preventing or treating neurological diseases, comprising porcine brain enzyme hydrolysate. The composition may exhibit neuroprotective ability, brain-derived neurotrophic factor (BDNF) production ability, acetylcholinesterase inhibitory ability, and reactive oxygen species (ROS) inhibitory ability.

Inventors

• 김건남
• 신재준
• 김경민
• 김민주
• 황윤미
• 윤선명
• 김대은
• 양진욱
• 배근원

Assignees

• 유니메드제약주식회사

Dates

Publication Date

20260507

Application Date

20260407

Priority Date

20220111

Claims (7)

1. Peptide of Sequence No. 1.
2. In claim 1, The above peptide is characterized by being purified or chemically synthesized from porcine brain enzyme hydrolysate.
3. In claim 1, The above peptide is a peptide characterized by being used as a food composition or a pharmaceutical composition.
4. In claim 1, The above peptide is a peptide characterized by being used for improving memory, improving cognitive ability, or preventing or treating neurological diseases.
5. In claim 4 A peptide characterized in that the above-mentioned neurological disease is selected from the group consisting of Alzheimer's disease, mild cognitive impairment, senile dementia, Parkinson's disease, Huntington's disease, Lewy body dementia, frontotemporal dementia, cerebral infarction, stroke, and epilepsy.
6. In claim 1, The above peptide is a peptide characterized by exhibiting neuroprotective ability and BDNF (brain-derived neurotrophic factor) generation ability.
7. In claim 1, The above peptide is a peptide characterized by exhibiting acetylcholinesterase inhibitory ability and reactive oxygen species (ROS) inhibitory ability.

Description

Composition for improving memory or cognitive ability, or preventing or treating brain neurological diseases comprising porcine brain enzyme hydrolysate The present invention relates to a composition for improving memory, improving cognitive ability, or preventing or treating neurological diseases, comprising porcine brain enzyme hydrolysate. The brain has various functions, but the most important are memory and cognitive abilities. If humans lack cognitive and memory abilities, it becomes difficult to perform daily activities, and survival becomes a problem. Cognitive memory impairment is the first and most common symptom experienced by patients with Alzheimer's disease. In the early stages of the disease, patients suffer from recent memory impairment, unable to recall details of recent conversations or events. This is attributed to damage to neurons in the hippocampus, which impairs the function of storing recent memories. However, during this period, remote long-term memory regarding events from the distant past is relatively well preserved. As the disease progresses, however, damage to the cerebral cortex associated with long-term memory storage leads to gradual impairment of these past memories as well. Meanwhile, among geriatric diseases, the most problematic issue is dementia, a cognitive impairment. Dementia refers to a persistent and overall decline in cognitive functions—such as memory, language ability, spatial awareness, judgment, and abstract thinking—due to brain damage; in severe cases, this can significantly impede daily life. Dementia is a type of brain disease known to be caused by various factors, including not only Alzheimer's disease and vascular dementia but also degenerative brain diseases like Parkinson's disease, as well as head trauma and infectious diseases. Therefore, it can be said that urgent efforts are needed to treat and manage dementia, which is rapidly increasing alongside the exponential growth of the elderly population. Dementia refers to a syndrome accompanied by various acquired symptoms of cognitive impairment, such as memory, language, and behavioral disorders, caused by the irreversible destruction of brain neurons resulting from brain atrophy, a decrease in nerve cells, and the appearance of senile plaques. Dementia is classified into Alzheimer's disease, degenerative diseases caused by vascular dementia and Parkinson's disease, metabolic diseases caused by hypothyroidism, and other types of dementia caused by brain tumors or infectious diseases. Currently, acetylcholinesterase (AChE) inhibitors such as donepezil, galantamine, and rivastigmine are used in clinical practice as drugs to improve dementia; however, due to low therapeutic efficacy and severe side effects, there is currently no effective treatment available. FIG. 1a is a process diagram schematically showing the manufacturing process of a porcine brain enzyme hydrolysate according to one embodiment of the present invention. FIG. 1b is an LC-MS chromatogram of a peptide (brPEP-1, PSIS) according to one embodiment of the present invention. FIG. 1c is an LC-MS chromatogram of a peptide (brPEP-2, GPAGPQGPR) according to one embodiment of the present invention. Figure 2 is a graph showing the results of a cytotoxicity evaluation for a peptide according to one embodiment of the present invention. FIGS. 3a and 3b are graphs showing the neuroprotective ability of a peptide according to one embodiment of the present invention (*, p <0.05; ** p <0.01; ***, p <0.001). FIGS. 3C and 3D are graphs showing the BDNF (brain-derived neurotrophic factor) production ability of a peptide according to one embodiment of the present invention (*, p <0.05; ** p <0.01; ***, p <0.001). FIG. 3e is a graph showing the β-amyloid aggregation of a peptide (brPEP-1) according to one embodiment of the present invention. FIG. 3f is a graph showing the ROS (Reactive Oxygen Species) of a peptide according to one embodiment of the present invention (*, p <0.05; ** p <0.01; ***, p <0.001). Figure 4 is a graph showing the results of a cytotoxicity evaluation of porcine brain enzyme hydrolysate according to one embodiment of the present invention. FIG. 5 is a graph showing the neuroprotective activity of porcine brain enzyme hydrolysate according to one embodiment of the present invention (*, p <0.05; ** p <0.01; ***, p <0.001). FIG. 6 is a graph showing the BDNF (brain-derived neurotrophic factor) production ability of porcine brain enzyme hydrolysate according to one embodiment of the present invention (*, p <0.05 ; ** p <0.01; ***, p <0.001). Figure 7 shows the protein (Caspase-3, ChAT) expression characteristics of a porcine brain enzyme hydrolysate according to one embodiment of the present invention. FIG. 8 is a graph showing the acetylcholinesterase inhibitory activity of porcine brain enzyme hydrolysate according to one embodiment of the present invention (*, p <0.05; ** p <0.01). FIG. 9 is a graph showing the reactive oxygen species (R